Alteon News (AMEX:ALT)
| Latest Alteon News Headlines | | Date | Time | Source | | | 24/07/2007 | 18:24 | PRNUS | Alteon Reverse Stock Split and Name Change to Become Effective on July 25th
MONTVALE, N.J., July 24 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announces that the reverse stock split of its common stock and name change will be in effect from Wednesday, July 25, 2007.
The Company will affect a reverse stock split of its common stock at a ratio of 1:50 to be effective on July 25, 2007... More...>> |
| 20/07/2007 | 20:20 | PRNUS | Alteon Stockholders Approve Amendments to Certificate of Incorporation at Annual Meeting
** Name Change to Synvista Therapeutics, Inc. and Reverse Stock Split to be Effective July 25 **
MONTVALE, N.J., July 20 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced that at its annual meeting of stockholders today, shareholders approved the following amendments to its Certificate of Incorporation:... More...>> |
| 18/07/2007 | 14:18 | PRNUS | Alteon to Hold Annual Meeting of Stockholders
COMPANY PRESENTATION TO BE WEBCAST LIVE
MONTVALE, N.J., July 18 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announces that its Annual Meeting of Stockholders will be held on Friday, July 20, 2007 at 10:00 a.m. ET at the Park Ridge Marriott, 300 Brae Boulevard, Park Ridge, New Jersey.
Following the formalities... More...>> |
| 16/07/2007 | 13:30 | PRNUS | Alteon Appoints Jacob Victor, Ph.D. to Lead Development of Haptoglobin Diagnostic Test
MONTVALE, N.J., July 16 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announces the appointment of Jacob Victor, Ph.D. as Executive Director, Product Development, Clinical Diagnostics, effective immediately. In this newly created position, Dr. Victor will lead the development of an immunoassay test for an initial... More...>> |
| 28/06/2007 | 13:30 | PRNUS | Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
Proof of Concept Study for Pharmacogenomic Indication
MONTVALE, N.J., June 28 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant... More...>> |
| 11/05/2007 | 19:23 | PRNUS | Alteon to Present at Rodman & Renshaw's Annual Health Care Conference
MONTVALE, N.J., May 11 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that Noah Berkwitz, MD, PhD, President and Chief Executive Officer, will deliver a corporate presentation at the Acumen BioFin Rodman & Renshaw 4th Annual Global Healthcare Conference in Monaco at 2:15 p.m. (8:15 a.m. Eastern) on... More...>> |
| 19/04/2007 | 22:57 | PRNUS | Alteon Issues Update Regarding Auditors' Going Concern Report
MONTVALE, N.J., April 19 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) In compliance with the AMEX Company Guide Rule 610(b) requiring a public announcement of the receipt of an audit report that contains an explanatory paragraph relating to Alteon's ability to continue as a going concern on the Company's consolidated... More...>> |
| 09/04/2007 | 13:30 | PRNUS | Alteon Announces Entry Into Definitive Documents for the Sale of $25 Million in a Private Financing of Its Series B Preferred St
MONTVALE, N.J., April 9 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that it has entered into a definitive agreement with institutional investors that are experienced in the biotechnology industry under which the Company has agreed to sell and issue $25 million in shares of its Series B Preferred... More...>> |
| 09/04/2007 | 13:30 | PRNUS | Alteon and OXIS International Expand Licensing Deal to Include Exclusive Rights of Organoselenium Compounds for All Indications
- Alteon to Develop Licensed Compounds with Recently Announced Financing -
MONTVALE, N.J., April 9 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) and OXIS International (OTC:OXIS.OB) (BULLETIN BOARD: OXIS.OB) announced that they have amended and restated an existing licensing agreement. Under the new terms of the... More...>> |
| 05/04/2007 | 23:00 | PRNUS | Alteon Expands Licensing Agreement With Biorap Technologies for Diagnostic Assays That Identify High Risk Cardiovascular Patient
--Haptoglobin Genotype Identifies Patients Most Likely to Benefit From Alteon's Investigational Drug ALT-2074--
MONTVALE, N.J., April 5 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that it has entered into an expanded licensing agreement with BioRap Technologies, Ltd., the commercialization arm of... More...>> |
| 20/02/2007 | 13:30 | PRNUS | Alteon's Investigational Drug Alagebrium Demonstrates Ability to Improve Functional Membrane Transport in a Rat Model of Chronic
- 'Best Abstract' Awarded at the 27th National Dialysis Conference February 18-20, 2007 in Denver, Colorado -
PARSIPPANY, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that a preclinical study presented at the 27th Annual Dialysis Conference in Denver, February 18-20, 2007 (http://www.muhealth.org/~dialysis... More...>> |
| 13/11/2006 | 13:30 | PRNUS | Alteon's ALT-2074 Demonstrates Ability to Reduce Infarct Size by 80 Percent in Mice with Haptoglobin 2-2 Genotype
- Abstracts Presented at the American Heart Association Scientific Sessions 2006 Suggest ALT-2074 May be Used For Significant Myocardial Protection -
PARSIPPANY, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that data demonstrating the ability of its compound ALT-2074 (formerly BXT-51072... More...>> |
| 13/09/2006 | 13:28 | PRNUS | Alteon Signs Agreements for Sale of Approximately $1.4 Million in Common Stock PIPE Transaction
PARSIPPANY, N.J., Sept. 13 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that it has entered into definitive agreements to sell $1.4 million of common stock. The agreements are subject to customary closing conditions.
The PIPE financing includes new and existing institutional investors, in which... More...>> |
| 11/09/2006 | 21:00 | PRNUS | New Alteon Management Focuses its Development of Alagebrium on Heart Failure with Preserved Ejection Fraction, also Known as Dia
- New Publications Identify the Pressing Need for Treatment of Diastolic Heart Failure -
PARSIPPANY, N.J., Sept. 11 /PRNewswire-FirstCall/ -- The new management of Alteon Inc. (AMEX:ALT), to further validate the Company's newly focused development of alagebrium on diastolic heart failure, highlights the recent publication... More...>> |
| 19/07/2006 | 21:05 | PRNUS | Alteon and HaptoGuard Shareholders Approve Merger
- Transaction Includes Granting of Certain Royalty and Negotiation Rights to Genentech, Inc. as Part of Restructuring of Genentech's Preferred Stock Position in Alteon -
PARSIPPANY, N.J., July 19 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that its shareholders have approved its previously-announced... More...>> |
| 10/07/2006 | 13:30 | PRNUS | Alteon Research Collaborator Receives Funding from Juvenile Diabetes Research Foundation for Diabetic Complications Clinical St
- Grant Part of JDRF's Initiative to Advance Effort to Find a Cure for Diabetes and its Complications -
PARSIPPANY, N.J., July 10 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that one of its collaborators, Mark Cooper, M.D., Ph.D., Professor, the Baker Heart Research Institute, Melbourne, Australia... More...>> |
| 15/05/2006 | 21:10 | PRNUS | Alteon Announces Financial Results for the First Quarter Ended March 31, 2006
PARSIPPANY, N.J., May 15 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today a net loss of $1,621,327 for the three months ended March 31, 2006. This compares to a net loss of $4,642,299 for the same period in 2005. The net loss applicable to common stockholders, which includes a non-cash preferred stock... More...>> |
| 09/05/2006 | 21:00 | PRNUS | HaptoGuard and UTI Limited Partnership Enter into License Agreement for Novel Class of Compounds Developed by University of Cal
HaptoGuard Plans to Develop New Class of Compounds with the Potential to Help Cardiovascular Patients
SADDLE BROOK, N.J., PARSIPPANY, N.J., and CALGARY, Alberta, May 9
/PRNewswire-FirstCall/ -- HaptoGuard Inc., Alteon Inc. (AMEX:ALT) and UTI Limited Partnership today announced that HaptoGuard has signed a worldwide exclusive... More...>> |
| 03/05/2006 | 21:04 | PRNUS | Alteon to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference
- Presentation to be Webcast -
PARSIPPANY, N.J., May 3 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced today that Kenneth I. Moch, President and Chief Executive Officer, will participate in the Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monaco. Mr. Moch is scheduled to present on Monday... More...>> |
| 19/04/2006 | 21:00 | PRNUS | Alteon and HaptoGuard Announce Merger Agreement; Alteon Signs Agreements for Sale of Approximately $2.6 Million in Common Stock
- Genentech Converts Portion of Alteon Preferred Stock, Transfers Portion of Preferred Stock to HaptoGuard and Cancels Remaining Preferred Stock, Acquires Right of First Negotiation for HaptoGuard Cardiovascular Compound and Future Royalties on Alteon's Alagebrium -
PARSIPPANY, N.J., April 19 /PRNewswire-FirstCall/... More...>> |
|
|
|